Core Insights - DarioHealth Corp. has formed a strategic partnership with a leading benefit administrator to provide a comprehensive cardiometabolic solution, which includes a GLP-1 support program and an AI-driven digital health suite, contributing to recurring revenues since January 2025 [1][2][4] - The partnership aims to address rising healthcare costs associated with metabolic conditions, particularly focusing on the demand for effective GLP-1 medication support [2][4] - Dario's approach includes a complete lifecycle management solution that supports members from medication initiation to long-term weight maintenance, addressing the challenge of medication discontinuation [3][4] Company Overview - DarioHealth Corp. is a leader in the digital health market, offering a user-centric platform for managing chronic conditions through personalized interventions driven by data analytics [5][6] - The company's platform aims to disrupt traditional episodic healthcare by providing continuous and customized care, promoting sustainable behavior change [6][7] Market Potential - The GLP-1 market is projected to grow to $100 billion by 2030, while the broader cardiometabolic disease market is expected to exceed $1.2 trillion by 2033 [3][4] - Research indicates that without proper behavioral support, 50-75% of patients discontinue GLP-1 medications within one year, highlighting the need for effective management solutions [3]